Un estudio de INCB099280 en combinación con axitinib en adultos con tumores sólidos avanzados
Un estudio de fase 1/2 de INCB099280 en combinación con axitinib en adultos con tumores sólidos avanzados
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Incyte Corporation Call Center (ex-US)
- Número de teléfono: +800 00027423
- Correo electrónico: eumedinfo@incyte.com
Ubicaciones de estudio
-
-
-
Cambridge, Reino Unido, CB2 0QQ
- Addenbrookes Hospital
-
Glasgow, Reino Unido, G12 0YN
- Beatson West of Scotland Cancer Centrewester
-
London, Reino Unido, SE1 9RT
- Guys Hospital
-
London, Reino Unido, EC1A 7BE
- St Bartholomew's Hospital
-
London, Reino Unido, SW3 6JJ
- The Royal Marsden
-
Sutton, Reino Unido, SM2 5PT
- The Royal Marsden Nhs Foundation Trust - Sutton
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Criterios de inclusión:
- Tumores sólidos avanzados histológicamente confirmados (tumores sólidos seleccionados definidos por protocolo) con lesiones medibles según los Criterios de Evaluación de Respuesta en Tumores Sólidos Versión 1.1 (RECIST v1.1) que se consideran no susceptibles de cirugía u otros tratamientos o procedimientos curativos.
- Debe haber progresión de la enfermedad durante o después del tratamiento con al menos una quimioterapia sistémica previa.
- Puntuación del estado funcional del Eastern Cooperative Oncology Group de 0 o 1.
- Esperanza de vida > 12 semanas.
- Voluntad de evitar el embarazo.
Criterio de exclusión:
- Neoplasia maligna adicional conocida que está progresando o requiere tratamiento activo.
- Metástasis del sistema nervioso central (SNC) que requieren tratamiento y/o enfermedad leptomeníngea.
- Toxicidad de la terapia previa que no se ha recuperado hasta los límites definidos por el protocolo.
- Recepción previa de un agente anti-PD-1, anti-PD-L1 o anti-PD-L2; tratamiento con un inmunomodulador (p. ej., CTLA-4, GITR, LAG3, TIM3, OX40, ICOS, IL-2, 4-1BB, célula CAR-T).
- Terapia previa con TKI de molécula pequeña antiangiogénicos dirigidos a la vía VEGF
- Participación en otro estudio clínico de intervención mientras recibía INCB099280.
- Deterioro de la función cardíaca o enfermedad cardíaca clínicamente significativa.
- Antecedentes o evidencia de enfermedad pulmonar intersticial, incluida neumonitis no infecciosa.
- Presencia de condiciones gastrointestinales que puedan afectar la absorción del fármaco.
- Cualquier enfermedad autoinmune que requiera tratamiento sistémico en los últimos 5 años.
- Diagnóstico de inmunodeficiencia primaria o tratamiento crónico con esteroides sistémicos a una dosis diaria superior a 10 mg de prednisona o equivalente.
- Infección activa que requiere tratamiento sistémico.
- Antecedentes de trasplante de órganos, incluido el trasplante de células madre.
- Recepción de antibióticos sistémicos dentro de los 28 días posteriores a la primera dosis del tratamiento del estudio.
- El uso de probióticos está prohibido durante la selección y durante todo el período de tratamiento del estudio.
- Recibió una vacuna viva dentro de los 28 días del inicio planificado del fármaco del estudio.
- Valores de laboratorio fuera de los rangos definidos por el Protocolo.
- Función orgánica inadecuada.
Pueden aplicarse otros criterios de inclusión/exclusión definidos en el protocolo.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Parte 1: escalada de dosis
Se evaluarán hasta 6 dosis de INCB099280 administradas dos veces al día (BID) en combinación con axitinib BID para identificar las dosis para una evaluación adicional en la fase de expansión de dosis del estudio.
|
Administrado como se especifica en la descripción del brazo de tratamiento
Administrado como se especifica en la descripción del brazo de tratamiento
|
|
Experimental: Parte 2: Expansión de dosis
Al completar la Parte 1, los participantes se inscribirán en 1 de 2 cohortes específicas de la enfermedad: Cohorte 1: Adultos con cánceres ginecológicos de células claras con al menos un 50 % de histología de células claras cuya enfermedad progresó en o después de al menos 1 línea previa de quimioterapia sistémica y no son candidatos para cirugía curativa o (quimio)radiación.
Cohorte 2: Adultos con cánceres epiteliales del tracto ginecológico de subtipo histológico raro cuya enfermedad progresó durante o después de al menos 1 línea previa de quimioterapia sistémica y no son candidatos para cirugía curativa o (quimio)radiación.
Se pueden seleccionar una o dos dosis de la Parte 1 para cada cohorte en la Expansión de la Parte 2.
|
Administrado como se especifica en la descripción del brazo de tratamiento
Administrado como se especifica en la descripción del brazo de tratamiento
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
Periodo de tiempo: up to 3 weeks
|
Any adverse event that ws at least possibly related to study treatment and met protocol-specified criteria was classified as a DLT.
For the purpose of dose finding, decisions on dose were based on DLTs observed during the first 21 days of treatment.
|
up to 3 weeks
|
|
Part 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
Periodo de tiempo: up to approximately 1 year
|
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related.
An AE therefore could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.
A TEAE was defined as an AE that was either reported for the first time or the worsening of a pre-existing event after the first dose of either study drug until 104 days after the last dose of study treatment or the start of new anticancer therapy.
|
up to approximately 1 year
|
|
Part 1: Number of Participants With TEAEs Leading to a Dosing Modification (Treatment Interruption, Dose Reduction, and Permanent Discontinuation of Either Study Drug)
Periodo de tiempo: up to approximately 1 year
|
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related.
An AE therefore could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.
A TEAE was defined as an AE that was either reported for the first time or the worsening of a pre-existing event after the first dose of either study drug until 104 days after the last dose of study treatment or the start of new anticancer therapy.
|
up to approximately 1 year
|
|
Part 2: Objective Response
Periodo de tiempo: up to 2 years
|
Objective response was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1).
CR: disappearance of all target and non-target lesions and no appearance of any new lesions.
Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 millimeters (mm).
PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
|
up to 2 years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 2: Number of Participants With Any TEAE
Periodo de tiempo: up to 2 years
|
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related.
An AE therefore could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.
A TEAE was defined as an AE that was either reported for the first time or the worsening of a pre-existing event after the first dose of either study drug until 104 days after the last dose of study treatment or the start of new anticancer therapy.
|
up to 2 years
|
|
Part 2: Number of Participants With TEAEs Leading to a Dosing Modification (Treatment Interruption, Dose Reduction, and Permanent Discontinuation of Either Study Drug)
Periodo de tiempo: up to 2 years
|
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related.
An AE therefore could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.
A TEAE was defined as an AE that was either reported for the first time or the worsening of a pre-existing event after the first dose of either study drug until 104 days after the last dose of study treatment or the start of new anticancer therapy.
|
up to 2 years
|
|
Part 1: Objective Response
Periodo de tiempo: up to 335 days
|
Objective response was defined as the percentage of participants with a BOR of CR or PR by investigator assessment per RECIST v1.1.
CR: disappearance of all target and non-target lesions and no appearance of any new lesions.
Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 millimeters (mm).
PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
|
up to 335 days
|
|
Part 1: Disease Control
Periodo de tiempo: up to 335 days
|
Disease control was defined as the percentage of participants with a BOR of CR, PR, or stable disease (SD) by investigator assessment per RECIST v1.1.
CR: disappearance of all target and non-target lesions and no appearance of any new lesions.
Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm.
PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
PD: progression of a target or non-target lesion or presence of a new lesion.
SD: no change in target lesions to qualify for CR, PR, or PD.
|
up to 335 days
|
|
Part 1: Duration of Response (DOR)
Periodo de tiempo: up to 335 days
|
DOR was defined as the time from the first CR or PR until disease progression by investigator assessment per RECIST v1.1 or death from any cause, whichever occurred earlier.
CR: disappearance of all target and non-target lesions and no appearance of any new lesions.
Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm.
PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
PD: progression of a target or non-target lesion or presence of a new lesion.
|
up to 335 days
|
|
Part 1: INCB099280 and Axitinib Plasma Concentrations
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
Blood samples were collected for the analysis of INCB099280 and axitinib concentrations.
Per Protocol, PK samples for axitinib were only to be analyzed in case of a concern that axitinib was not as active as expected.
Due to the early termination of the study before readout, these samples were not analyzed.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
|
Part 1: Cmax of INCB099280 When Administered With Axitinib
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
Cmax was defined as the maximum observed concentration of INCB099280.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
|
Part 1: Tmax of INCB099280 When Administered With Axitinib
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
tmax was defined as the time to the maximum concentration of INCB099280.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
|
Part 1: AUC0-4h of INCB099280 When Administered With Axitinib
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
AUC0-4h was defined as area under the steady-state plasma or serum concentration-time curve from 0 to 4 hours.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
|
Part 1: Cmax,ss of INCB099280 When Administered With Axitinib
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
Cmax,ss was defined as the maximum observed concentration at steady state.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
|
Part 1: Tmax,ss of INCB099280 When Administered With Axitinib
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
tmax,ss was defined as the time to the maximum concentration of INCB099280 at steady state.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
|
Part 1: AUC0-12h of INCB099280 When Administered With Axitinib
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
AUC0-12h was defined as the area under the steady-state plasma or serum concentration-time curve from 0 to 12 hours.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
|
Part 1: Cavg of INCB099280 When Administered With Axitinib
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
Cavg was defined as the average concentration of INCB099280.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
|
Part 1: Ctau of INCB099280 When Administered With Axitinib
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
Ctau was defined as the concentration of INCB099280 at the end of a dose interval.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
|
Part 1: t1/2 of INCB099280 When Administered With Axitinib
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
t1/2 was defined as the apparent terminal-phase disposition half life of INCB099280.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
|
Part 1: CLss/F of INCB099280 When Administered With Axitinib
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
CLss/F was defined as the apparent oral dose clearance of INCB099280 at steady state.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
|
Part 1: Vz/F of INCB099280 When Administered With Axitinib
Periodo de tiempo: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
Vz/F was defined as the apparent oral dose volume of distribution of INCB099280.
|
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Philomena Colucci, Incyte Corporation
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- inhibidor de la tirosina quinasa
- terapia de combinación
- cáncer de ovarios
- cáncer de trompa de Falopio
- cáncer de cuello uterino
- cáncer uterino
- carcinosarcoma
- cáncer de vagina
- cáncer de vulva
- cáncer del tracto ginecológico
- cáncer primario de peritoneo
- histología de células claras
- adenocarcinoma mucinoso
- adenocarcinoma seroso
- histología neuroendocrina
- histología de células pequeñas
- inhibidor de molécula pequeña pdl1
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades del sistema endocrino
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Neoplasias por tipo histológico
- Enfermedades uterinas
- Enfermedades Genitales Femeninas
- Neoplasias de glándulas endocrinas
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Enfermedades Ováricas
- Enfermedades anexiales
- Neoplasias Genitales Femeninas
- Trastornos gonadales
- Carcinoma
- Enfermedades del cuello uterino
- Sarcoma
- Neoplasias De Tejidos Conectivos Y Blandos
- Cistoadenocarcinoma
- Neoplasias quísticas, mucinosas y serosas
- Neoplasias Complejas y Mixtas
- Enfermedades Vulvares
- Enfermedades de las trompas de Falopio
- Enfermedades vaginales
- Neoplasias Ováricas
- Neoplasias del cuello uterino
- Cistadenocarcinoma Seroso
- Carcinosarcoma
- Neoplasias Vulvares
- Adenocarcinoma Mucinoso
- Neoplasias de las trompas de Falopio
- Neoplasias Uterinas
- Neoplasias vaginales
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Azoles
- Hidrocarburos
- Hidrocarburos, cíclico
- Ácidos carboxílicos
- Hidrocarburos, aromáticos
- Amidas
- Derivados de benceno
- Ácidos, carbocíclicos
- Benzoates
- Benzamidas
- Indazoles
- Pirazoles
- Axitinib
Otros números de identificación del estudio
Otros números de identificación del estudio
- INCB99280-201
- 2022-003663-13 (Número EudraCT: CTIS (EU))
- 2023-510281-27-00 (Identificador de registro: EU CT Number)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Marco de tiempo para compartir IPD
Criterios de acceso compartido de IPD
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .